<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H32F3F76F441A4661A1C99C123625B731" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 2471 IH: Right Drug Dose Now Act of 2025</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-03-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2471</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250327">March 27, 2025</action-date><action-desc><sponsor name-id="S001193">Mr. Swalwell</sponsor> (for himself and <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To update the National Action Plan for Adverse Drug Event Prevention to consider advances in pharmacogenomic research and testing, to improve electronic health records for pharmacogenomic information, and for other purposes.</official-title></form><legis-body id="H7C16EF4A683A4BF8AD76EFC7DEFD9960" style="OLC"> 
<section id="HDE9EE1F1660147FFB0B8CB0B0A66B2D9" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Right Drug Dose Now Act of 2025</short-title></quote>.</text></section> <section id="HCF94EC35B733478ABD4AD1864DD819F0"><enum>2.</enum><header>Table of contents</header><text display-inline="no-display-inline">The table of contents of this Act is as follows:</text>
<toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded">
<toc-entry idref="HDE9EE1F1660147FFB0B8CB0B0A66B2D9" level="section">Sec. 1. Short title.</toc-entry>
<toc-entry idref="HCF94EC35B733478ABD4AD1864DD819F0" level="section">Sec. 2. Table of contents.</toc-entry>
<toc-entry idref="H8076E8D599A14B36AE12B002072B1AEC" level="section">Sec. 3. National Action Plan for Adverse Drug Event Prevention.</toc-entry>
<toc-entry idref="H45ACB032BCE2402C933820C580F2999B" level="section">Sec. 4. Adverse drug event and pharmacogenomic testing education for health care professionals.</toc-entry>
<toc-entry idref="H0DB1E404A2204A99872AF0E783B2AEBB" level="section">Sec. 5. Improving EHR systems to improve the use of pharmacogenomic information.</toc-entry></toc></section>
<section id="H8076E8D599A14B36AE12B002072B1AEC"><enum>3.</enum><header>National Action Plan for Adverse Drug Event Prevention</header><text display-inline="no-display-inline">The Secretary of Health and Human Services (in this Act referred to as the <quote>Secretary</quote>) shall—</text> <paragraph id="H0A4DB5CE908842BABBAAC84F7170B49F"><enum>(1)</enum><text display-inline="yes-display-inline">not later than 180 days after the date of enactment of this Act, in coordination with the heads of other relevant Federal departments and agencies, submit a report to the Congress on the implementation of the National Action Plan for Adverse Drug Event Prevention of the Department of Health and Human Services, including on the progress in meeting the target outcomes approved by the Federal Interagency Steering Committee for Adverse Drug Events;</text></paragraph>
<paragraph id="H7688EE2375A745CFB1D70353DC24B101"><enum>(2)</enum><text display-inline="yes-display-inline">convene the Federal Interagency Steering Committee for Adverse Drug Events to update the National Action Plan for Adverse Drug Event Prevention; and</text></paragraph> <paragraph id="H27EB7FDAAE304B4185D0BC85E474ECF2"><enum>(3)</enum><text display-inline="yes-display-inline">require such Committee, in updating the National Action Plan for Adverse Drug Event Prevention—</text>
<subparagraph id="H4541F6FC7DE745BBB2AC7E5AB3C3E993"><enum>(A)</enum><text>to consider advances in scientific understanding and technology pertaining to drug-gene interactions (including interactions among multiple drugs and genes), clinical outcomes, health care utilization, and the decreasing cost of genetic testing;</text></subparagraph> <subparagraph id="H6D4FF6027E7543FBA3112CACDA179DA7"><enum>(B)</enum><text>to assess the role of pharmacogenetics testing combined with clinical decision support as an evidence-based prevention tool; and</text></subparagraph>
<subparagraph id="HFFBACBC3A05C40189962EF9C7CA4EEC5"><enum>(C)</enum><text>to evaluate operating characteristics for Federal adverse drug event monitoring systems and expand capabilities to identify genetic associations in adverse events.</text></subparagraph></paragraph></section> <section id="H45ACB032BCE2402C933820C580F2999B" display-inline="no-display-inline" section-type="subsequent-section"><enum>4.</enum><header>Adverse drug event and pharmacogenomic testing education for health care professionals</header><text display-inline="no-display-inline">The Secretary shall issue guidance for health care providers and health care leaders, including administrators, primary and specialty care physicians, pharmacists, nurse practitioners, physician assistants, physician medical geneticists, laboratory medical geneticists, genetic counselors, medical educators, and the faculty of schools of medicine and other schools of health professions, on the following:</text>
<paragraph id="H72335D460BA64FBE95DE14AD131FDD61"><enum>(1)</enum><text>Pharmacogenomic testing and the extent of its ability to prevent adverse drug reactions.</text></paragraph> <paragraph id="H2D529032494F45CE9E926B7BF52A7EA2"><enum>(2)</enum><text display-inline="yes-display-inline">Pharmacogenomic testing, drug interaction alerting systems, when to refer to or consult with a genetics provider, and the applicable Federal standards of care for patients who are suspected or known to have a genetic variant that is known to impact drug metabolism or adverse reactions.</text></paragraph>
<paragraph id="HDE2148D6EBF543198F399E18A2512719"><enum>(3)</enum><text>Evidence-based information that would encourage individuals and their health care professionals to consider pharmacogenomic testing as part of their health care plan to the extent appropriate.</text></paragraph> <paragraph id="H4879FEA9556C49118748C206AC486374"><enum>(4)</enum><text>The role of medical professionals who specialize in genetics and genomics.</text></paragraph>
<paragraph id="H723EC899787E4C71A55A26695A384889"><enum>(5)</enum><text>How to incorporate pharmacogenomics into comprehensive medication management.</text></paragraph> <paragraph id="H89A99B7405BD4C07AE01AC73670FC44B"><enum>(6)</enum><text>The importance of reporting information about known and relevant pharmacogenomic information when reporting adverse drug events to the FDA Adverse Event Reporting System.</text></paragraph></section>
<section id="H0DB1E404A2204A99872AF0E783B2AEBB"><enum>5.</enum><header>Improving EHR systems to improve the use of pharmacogenomic information</header>
<subsection id="H7E796823CC5049D98D62C43EA287CB60"><enum>(a)</enum><header>Certification criteria</header><text display-inline="yes-display-inline">The Secretary shall provide guidance for health care providers and health care leaders, including administrators, primary and specialty care physicians, pharmacists, nurse practitioners, physician assistants, physician medical geneticists, laboratory medical geneticists, genetic counselors, medical educators, and the faculty of schools of medicine and other schools of health professions, on health information technologies, including for electronic prescribing systems and real-time pharmacy benefit checks, regarding how, before a medication order is completed and acted upon during computerized provider order entry, interventions might automatically indicate to a user—</text> <paragraph id="H602D2B121EB74437B18E6E25D6E7A53B"><enum>(1)</enum><text display-inline="yes-display-inline">when pharmacogenomic testing is appropriate based on a drug product’s label or peer-reviewed professional guidelines; and</text></paragraph>
<paragraph id="H43BD89FAEE1D42E289834EB14835F91D"><enum>(2)</enum><text display-inline="yes-display-inline">drug-gene and drug-drug-gene associations, established by a drug product’s label or peer-reviewed professional guidelines, based on a patient’s medication list, medication allergy list, and results from pharmacogenomic testing.</text></paragraph></subsection> <subsection id="H7DE5F125803044238D540D97A08DD6FA"><enum>(b)</enum><header>Guidance on drug-Gene interaction alerting systems</header> <paragraph id="HB654BCD1B1354FB68CDCD7C3F964E60C"><enum>(1)</enum><header>Issuance and updates</header><text>The Secretary shall—</text>
<subparagraph id="H56F654DC3CF241ADBD340428B40DC28A"><enum>(A)</enum><text>issue routine guidance on drug-gene interaction alerting systems in electronic health records; and</text></subparagraph> <subparagraph id="H3FEFFCD259194D699A886ADEA978B797"><enum>(B)</enum><text display-inline="yes-display-inline">not less than biannually, update such guidance to incorporate pharmacogenomic information from—</text>
<clause id="HCBB6FC7940D3451D9F341282DA308663"><enum>(i)</enum><text>new or updated drug labels; and</text></clause> <clause id="H152FB8C3E5FD46A599D2B807574D5B8B"><enum>(ii)</enum><text>newly established peer-reviewed professional guidelines on drug-gene associations.</text></clause></subparagraph></paragraph>
<paragraph id="HEFFDB37CB31A41089951A4A564C63CFE"><enum>(2)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in paragraph (1) shall be construed as prohibiting an entity from updating the results of pharmacogenomic testing, or alerting the provider, if a medication is contraindicated by the results of pharmacogenomic testing.</text></paragraph></subsection> <subsection id="H7997C66B02AE404FBB8766037FDC801D"><enum>(c)</enum><header>Reducing adverse drug events reporting burdens</header><text display-inline="yes-display-inline">The Secretary shall encourage the development of electronic health record systems that allow for adverse drug event information to be directly reported to the FDA Adverse Event Reporting System.</text></subsection>
<subsection id="H0F926D4B30B34F4B9F2575FB7601B233"><enum>(d)</enum><header>Updating FAERS; patient-Friendly reporting</header><text>The Secretary shall—</text> <paragraph id="H9DEE99E9DD784A8D9E6E57A34F5D46F3"><enum>(1)</enum><text>update the FDA Adverse Event Reporting System, including to—</text>
<subparagraph id="HFBF8A55631774681AFD5308A7C036FE7"><enum>(A)</enum><text display-inline="yes-display-inline">create an optional selection tool that allows individuals to report whether an adverse drug event is associated with a drug-gene or drug-drug-gene interaction; and </text></subparagraph> <subparagraph id="HB9171918A7524BC09B3C651C04C1721E"><enum>(B)</enum><text>accept information directly from health care providers’ electronic health record systems;</text></subparagraph></paragraph>
<paragraph id="H73CF77CD7550459FBB086CD2F00DBA32" commented="no"><enum>(2)</enum><text>work with relevant Federal agencies and offices, and stakeholders, to create patient-friendly electronic options for reporting adverse drug events such as submission through an optional designated mobile device application or mobile device messaging application; and</text></paragraph> <paragraph id="HC3703DCD776C4CF499ADB4419564E87F"><enum>(3)</enum><text>not later than 1 year after the date of enactment of this Act, report to the Congress on the progress made in implementing paragraphs (1) and (2).</text></paragraph></subsection>
<subsection id="H97ECC7B6E2ED46B6860DD3E81EC5DAF1"><enum>(e)</enum><header>GAO study and recommendations on inclusion of information on drug-Gene interactions on drug labels</header><text display-inline="yes-display-inline">Not later than 180 days after the date of enactment of this Act, the Comptroller General of the United States shall—</text> <paragraph id="H902D2A8363AE4C75A71EA35455C2204D"><enum>(1)</enum><text display-inline="yes-display-inline">study, and formulate recommendations on, how the Food and Drug Administration can include and update information on drug-gene interactions on drug labels; and</text></paragraph>
<paragraph id="H913E9BCF29E04739897275E2352D58A2"><enum>(2)</enum><text display-inline="yes-display-inline">submit recommendations to the relevant committees of jurisdiction.</text></paragraph></subsection> <subsection id="HD8259DDD3C8741C180653A81C80B29CC"><enum>(f)</enum><header>Report on additional improvements to electronic health record systems</header> <paragraph id="H517974EDF3954B528369807D80D9BFAC"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date of enactment of this Act, the Secretary shall—</text>
<subparagraph id="H0E797BE52BA74B91B9A54B2B3295121A"><enum>(A)</enum><text>complete a report on additional improvements to electronic health record systems that are needed to further the development of real world evidence (as defined in section 505F of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355g">21 U.S.C. 355g</external-xref>)) in pharmacogenomics; and</text></subparagraph> <subparagraph id="H941F84A652B64732A59EF3D68CB21C8C"><enum>(B)</enum><text display-inline="yes-display-inline">submit such report to the Congress.</text></subparagraph></paragraph>
<paragraph id="H441CB912C65B477E96E1216CF1DF92DE"><enum>(2)</enum><header>Consideration of needed advancements</header><text display-inline="yes-display-inline">As part of the report under paragraph (1), the Secretary shall consider what advancements are needed in electronic health record systems to capture information about the laboratory and the test used as part of pharmacogenomic testing.</text></paragraph></subsection></section> </legis-body></bill>

